Recent Updates
Recently added Catalysts
SMMT Positive Sentiment

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026

Wednesday, November 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Summit Therapeutics reported its financial results for Q3 and the nine months ending September 30, 2026. The company highlighted a $2 billion strategic investment from AstraZeneca and the expansion of clinical collaborations with AstraZeneca and Daiichi Sankyo. This reflects significant operational progress during the quarter.

Market Sentiment Analysis

POSITIVE FACTORS

  • AstraZeneca made a $2 billion strategic equity investment.
  • Expansion of clinical collaborations with major companies.
  • Meaningful momentum reported in operational progress.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+30%
120-day peak, hindsight
Typical move
27.8%
average across 6 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
Ivonescimab
Phase 3 · Non Small Cell Lung Cancer

Full Press Release Details

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on clinical and operational progress. “This quarter marked a period of meaningful momentum for Summit, highlighted by AstraZeneca’s $2 billion strategic equity investment and the expansion of our network of clinical collaborations with AstraZeneca, Daiichi Sankyo, and several others,” said Robert W. Duggan, Ch

Frequently Asked Questions

What were Summit Therapeutics' Q3 2026 results?

Summit reported financial results showing significant operational progress.

Who made a strategic investment in Summit Therapeutics?

AstraZeneca made a $2 billion strategic equity investment.

What collaborations did Summit expand?

Summit expanded collaborations with AstraZeneca, Daiichi Sankyo, and others.

When did Summit report its financial results?

Summit reported its financial results for Q3 and nine months ended September 30, 2026.

ShareAdd on Google
Tags: SMMT Summit Therapeutics AstraZeneca financial results clinical collaborations
Last updated: Nov 4, 2026

Biotech snapshot

Cash runway
$691M liquidity · $47M/mo burn
~11 mo
Medium dilution risk
Lead asset
IvonescimabPhase 3
Non Small Cell Lung Cancer →

Catalyst track record

+30%
best trade around SMMT's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for SMMT.

See every catalyst's timing & PoA →